top of page

Biopharma Daily Stock Updates - 08/10/21

$XBI $126.48 -0.81%


Pipeline Updates

$ADMA -0.7% ADMA Biologics Advances Expansion Plans and Opens New Plasma Collection Center in Conyers, GA; ADMA Implements Haemonetics’ Persona Technology for NexSys Plasma Collection System. source

$ATHX +4.6% Athersys Partner HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Treatment for Ischemic Stroke. source

$PHAS -2.4% PhaseBio Pharmaceuticals and SFJ Pharmaceuticals® Announce Approval of IND Application in China for Bentracimab. source

$IFRX -3.0% InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum. source

$KLDO -2.4% Kaleido Biosciences and the COPD Foundation Announce a Strategic Collaboration to Advance KB109 into Phase 2 Clinical Trial. source

$IMV +8.9% IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer. source

$TRVN +2.1% Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK® in Pain and Therapy. source

$FULC +125.3% Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease. source

$FNCH +1.5% Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program. source

$JAZZ -4.2% GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex. source

$IMPL -25.9% Impel NeuroPharma to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021. source

$RETA -18.1% Reata Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs. source

$ZIOP -16.2% Ziopharm Oncology Provides Second Quarter 2021 Corporate Updates. source

$NEXI +18.1% NexImmune Reports Second Quarter 2021 Financial Results and Provides Business Updates. source

$CRTX +21.5% Cortexyme Provides Business Update and Reports Second Quarter 2021 Results. source

$ACHL +22.1% Achilles Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights. source

$ORPH +24.6% On 8/5 New publication date for Orphazyme’s Interim Report H1 2021. source

Financial Updates

$FULC +125.3% Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock. source

$PTGX +1.1% Protagonist Therapeutics Announces Resolution of Contract Dispute with Zealand Pharma. source

$LMNL -17.8% Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M. source

$BCRX -13.9% BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants. source


Posted by FS

bottom of page